LUCD NASDAQ
Lucid Diagnostics Inc.
1W: -2.0%
1M: -23.7%
3M: -26.5%
YTD: -10.7%
1Y: -23.1%
3Y: -33.3%
$1.07
+0.07 (+7.00%)
Weekly Expected Move ±9.5%
$1
$1
$1
$1
$1
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Bullish
75
Insider+$0.2M
Congress—
ETF Holdings—
Key Statistics
Market Cap$109.5M
52W Range0.9-1.7
Volume1,528,678
Avg Volume800,861
Beta1.10
Dividend—
Analyst Ratings
Company Info
CEOLishan Aklog
Employees72
SectorHealthcare
IndustryMedical - Devices
IPO Date2021-10-14
Websiteluciddx.com
One Grand Central Place
New York City, NY 10165
US
New York City, NY 10165
US
212 949 4319
About Lucid Diagnostics Inc.
Lucid Diagnostics Inc. operates as a commercial-stage medical diagnostics technology company. The company focuses on patients with gastroesophageal reflux disease, which is also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically highly lethal esophageal adenocarcinoma. Its lead products include EsoGuard, a laboratory developed esophageal DNA test; and EsoCheck, an esophageal cell collection device. The company was incorporated in 2018 and is based in New York, New York. Lucid Diagnostics Inc. is a subsidiary of PAVmed Inc.
Latest News
PAVmed Provides Business Update and Reports First Quarter 2026 Financial Results
Lucid Diagnostics Inc. Q1 2026 Earnings Call Summary
LUCD Q1 2026 Earnings Transcript
Lucid Diagnostics Inc. (LUCD) Reports Q1 Loss, Misses Revenue Estimates
Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Matheis Dennis | P-Purchase | 245,000 | $1.00 | 2026-05-20 |
| Lee Victoria Tou-ho | 100,000 | $1.25 | 2026-03-23 | |
| Lee Victoria Tou-ho | 0 | — | 2026-03-23 | |
| Aklog Lishan | A-Award | 2,170,000 | — | 2026-02-20 |
| Matheis Dennis | A-Award | 123,000 | — | 2026-02-20 |